Each year, the Pink October campaign mobilizes millions around breast cancer awareness, a disease diagnosed in more than 60,000 people annually in France. Yet despite the consensus surrounding the fight against breast cancer, the annual campaign is increasingly drawing sharp criticism from activists, researchers, and patients alike.
A Campaign Accused of Ignoring Root Causes
French MP Mathilde Panot of La France Insoumise recently sparked debate with a divisive video criticizing Pink October, thrusting long-simmering grievances into the spotlight. Among the most vocal critics is Fleur Breteau, who founded the collective Cancer Colère in 2025. For Breteau, a two-time breast cancer survivor, and the activists who joined her movement, the campaign completely obscures the environmental causes of cancer.
In a pamphlet, the collective denounced the annual awareness operation as an “imposture by polluters and public authorities to never tackle the environmental causes of our cancers.” The group specifically points to pesticides and phytosanitary products used in agriculture, which Inserm has flagged as suspected contributors to breast cancer.
“When we are told that if we have breast cancer, it’s because we ate too much ice cream, were too stressed, drank alcohol or smoked cigarettes […] when environmental causes are obscured to this extent, it raises serious questions,” Breteau told France Inter.
Focus on Individual Behavior Over Systemic Factors
Marc Billaud, a CNRS researcher and co-author of a recent graphic novel on cancers linked to environmental and societal factors, criticized Pink October’s messaging as “essentially focused on individual behavior — that is, screening and self-examination.”
From a screening perspective, the campaign has largely fallen short, according to Cancer Colère. While women aged 50 to 74 are invited to undergo a mammogram every two years, recent figures from the Court of Auditors show that screening participation dropped to just 44% of the target population in 2024, down from 52.3% in 2011.
The collective attributes this decline to “social inequalities but also territorial inequalities: 10% of women aged 50 to 74 live more than 25 minutes from an organized screening site.”
The Pinkwashing Problem
Another major criticism concerns the “pinkwashing” practiced by companies supporting the operation. Each October, a panoply of pink-colored products floods store shelves, with a portion of profits — sometimes modest — pledged to breast cancer research.
“It’s a campaign that will inevitably benefit the brand, which will be associated with something positive in terms of image,” said Fabien Pecot, a marketing professor at TBS Education, speaking to RMC. “Ultimately, the brand can check one of the boxes dedicated to women’s policies in its annual report.”
Problematic Narratives Around Cancer
Further criticism targets Pink October’s messaging. Radiologist Amélie Cadier-Loriaud noted on Arte that the campaign “narrates breast cancer as something women emerge from stronger.” She emphasized that breast cancer also involves suffering and, sometimes, women being abandoned by their partners during treatment.
The “warrior woman” narrative, Cadier-Loriaud argued, fails to highlight “something that relates to vulnerability.”
For Lucie, a breast cancer survivor, the testimonials shared during Pink October “very often awakened a strong sense of guilt.” She told Madmoizelle in 2023: “You had to be positive, exercise every day to counter fatigue, ‘stay feminine,’ not look sick…” Ultimately, she said, the campaign contributes to “reproducing certain representations about the illness and the [sexist] injunctions that weigh on those who suffer from it.”
A Cause That Still Matters
Despite these criticisms, the stakes remain high. Breast cancer affects tens of thousands of people each year in France, and those diagnosed face numerous challenges — from treatment side effects to social and professional repercussions. The debate surrounding Pink October ultimately raises a broader question: how can awareness campaigns better address the systemic and environmental dimensions of a disease that touches so many lives?
